@prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix schem: . @prefix go: . @prefix obo: . @prefix occursIn: . @prefix species: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 occursIn: obo:CL_0000746, obo:UBERON_0004237, species:10116; rdf:object go:0006939; rdf:predicate belv:increases; rdf:subject schem:Calcium; a rdf:Statement . sub:assertion rdfs:label "a(SCHEM:Calcium) -> bp(GOBP:\"smooth muscle contraction\")" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_3; pav:version "20131211" . sub:_2 prov:value "Although direct pharmacological inhibition of PDE2 activity with erythro-9-(2-hydroxyl-3-nonyl)adenine increases L-type Ca2+ currents in cardiomyocytes, and contracts these cells, the overall magnitude of this effect is species-specific and probably influenced by several factors, including basal levels of adenylyl and guanylyl cyclases as well as the level of PDE3 activity in these cells (Vandecasteele et al., 2001)."; prov:wasQuotedFrom pubmed:12920188 . sub:_3 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:12920188; prov:wasDerivedFrom beldoc:, sub:_2 . } sub:pubinfo { this: dct:created "2014-07-03T14:32:06.815+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }